Literature DB >> 22383521

Ubiquitination of BST-2 protein by HIV-1 Vpu protein does not require lysine, serine, or threonine residues within the BST-2 cytoplasmic domain.

Jean K Gustin1, Janet L Douglas, Ying Bai, Ashlee V Moses.   

Abstract

The cellular protein BST-2/CD317/Tetherin has been shown to inhibit the release of HIV-1 and other enveloped viruses from infected cells. The HIV-1 accessory protein Vpu binds to both BST-2 and βTrCP, a substrate-recognition subunit for the SCF (Skip1-Cullin1-F-box protein) E3 ubiquitin ligase complex. This interaction leads to both the degradation of BST-2 and the enhancement of viral egress. Recently BST-2 was shown to be ubiquitinated in this process. Here we have confirmed the Vpu- and βTrCP-dependent multi/polyubiquitination of BST-2. Ubiquitinated BST-2 accumulated in cells treated with a lysosomal inhibitor but not a proteasomal inhibitor. Additionally, we observed that a BST-2 mutant deleted for its cytosolically exposed lysine residues is also ubiquitinated. Subsequent experiments suggested that Vpu promotes BST-2 ubiquitination upon amino acid residues bearing hydroxyl- but not thiol-bearing side chains. However, a BST-2 mutant bearing substitutions for its cytoplasmically exposed Ser, Thr, and Lys residues was still down-regulated, ubiquitinated, and degraded in a Vpu-dependent manner. Our results suggest that Vpu may target either the BST-2 cytoplasmic Tyr residues or the NH(2) terminus itself for ubiquitination.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22383521      PMCID: PMC3340234          DOI: 10.1074/jbc.M112.349928

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  71 in total

1.  Tight control of gene expression in mammalian cells by tetracycline-responsive promoters.

Authors:  M Gossen; H Bujard
Journal:  Proc Natl Acad Sci U S A       Date:  1992-06-15       Impact factor: 11.205

2.  An interferon-alpha-induced tethering mechanism inhibits HIV-1 and Ebola virus particle release but is counteracted by the HIV-1 Vpu protein.

Authors:  Stuart J D Neil; Virginie Sandrin; Wesley I Sundquist; Paul D Bieniasz
Journal:  Cell Host Microbe       Date:  2007-09-13       Impact factor: 21.023

3.  CD4 glycoprotein degradation induced by human immunodeficiency virus type 1 Vpu protein requires the function of proteasomes and the ubiquitin-conjugating pathway.

Authors:  U Schubert; L C Antón; I Bacík; J H Cox; S Bour; J R Bennink; M Orlowski; K Strebel; J W Yewdell
Journal:  J Virol       Date:  1998-03       Impact factor: 5.103

4.  Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu.

Authors:  Stuart J D Neil; Trinity Zang; Paul D Bieniasz
Journal:  Nature       Date:  2008-01-16       Impact factor: 49.962

5.  HIV-1 antagonism of CD317 is species specific and involves Vpu-mediated proteasomal degradation of the restriction factor.

Authors:  Christine Goffinet; Ina Allespach; Stefanie Homann; Hanna-Mari Tervo; Anja Habermann; Daniel Rupp; Lena Oberbremer; Christian Kern; Nadine Tibroni; Sonja Welsch; Jacomine Krijnse-Locker; George Banting; Hans-Georg Kräusslich; Oliver T Fackler; Oliver T Keppler
Journal:  Cell Host Microbe       Date:  2009-03-19       Impact factor: 21.023

6.  HM1.24 is internalized from lipid rafts by clathrin-mediated endocytosis through interaction with alpha-adaptin.

Authors:  Naoko Masuyama; Toshio Kuronita; Rika Tanaka; Tomonori Muto; Yuko Hirota; Azusa Takigawa; Hideaki Fujita; Yoshinori Aso; Jun Amano; Yoshitaka Tanaka
Journal:  J Biol Chem       Date:  2009-04-08       Impact factor: 5.157

7.  Determinants of growth hormone receptor down-regulation.

Authors:  Luqin Deng; Kai He; Xiangdong Wang; Ning Yang; Chellappagounder Thangavel; Jing Jiang; Serge Y Fuchs; Stuart J Frank
Journal:  Mol Endocrinol       Date:  2007-05-08

8.  The specificities of Kaposi's sarcoma-associated herpesvirus-encoded E3 ubiquitin ligases are determined by the positions of lysine or cysteine residues within the intracytoplasmic domains of their targets.

Authors:  Ken Cadwell; Laurent Coscoy
Journal:  J Virol       Date:  2008-02-13       Impact factor: 5.103

9.  A novel membrane antigen selectively expressed on terminally differentiated human B cells.

Authors:  T Goto; S J Kennel; M Abe; M Takishita; M Kosaka; A Solomon; S Saito
Journal:  Blood       Date:  1994-09-15       Impact factor: 22.113

10.  Suppression of Tetherin-restricting activity upon human immunodeficiency virus type 1 particle release correlates with localization of Vpu in the trans-Golgi network.

Authors:  Mathieu Dubé; Bibhuti Bhusan Roy; Pierre Guiot-Guillain; Johanne Mercier; Julie Binette; Grace Leung; Eric A Cohen
Journal:  J Virol       Date:  2009-02-25       Impact factor: 5.103

View more
  26 in total

Review 1.  The evolving role of ubiquitin modification in endoplasmic reticulum-associated degradation.

Authors:  G Michael Preston; Jeffrey L Brodsky
Journal:  Biochem J       Date:  2017-02-15       Impact factor: 3.857

Review 2.  The restriction factors of human immunodeficiency virus.

Authors:  Reuben S Harris; Judd F Hultquist; David T Evans
Journal:  J Biol Chem       Date:  2012-10-05       Impact factor: 5.157

3.  Ebola Virus Glycoprotein Promotes Enhanced Viral Egress by Preventing Ebola VP40 From Associating With the Host Restriction Factor BST2/Tetherin.

Authors:  Jean K Gustin; Ying Bai; Ashlee V Moses; Janet L Douglas
Journal:  J Infect Dis       Date:  2015-03-27       Impact factor: 5.226

4.  A comparative mutational analysis of HIV-1 Vpu subtypes B and C for the identification of determinants required to counteract BST-2/Tetherin and enhance viral egress.

Authors:  Janet L Douglas; Ying Bai; Jean K Gustin; Ashlee V Moses
Journal:  Virology       Date:  2013-04-10       Impact factor: 3.616

5.  Tetherin antagonism by Vpu protects HIV-infected cells from antibody-dependent cell-mediated cytotoxicity.

Authors:  Juan F Arias; Lisa N Heyer; Benjamin von Bredow; Kim L Weisgrau; Brian Moldt; Dennis R Burton; Eva G Rakasz; David T Evans
Journal:  Proc Natl Acad Sci U S A       Date:  2014-04-14       Impact factor: 11.205

6.  Identification of alternatively translated Tetherin isoforms with differing antiviral and signaling activities.

Authors:  Luis J Cocka; Paul Bates
Journal:  PLoS Pathog       Date:  2012-09-27       Impact factor: 6.823

7.  Tetherin/BST-2 antagonism by Nef depends on a direct physical interaction between Nef and tetherin, and on clathrin-mediated endocytosis.

Authors:  Ruth Serra-Moreno; Kerstin Zimmermann; Lawrence J Stern; David T Evans
Journal:  PLoS Pathog       Date:  2013-07-11       Impact factor: 6.823

8.  Differential sensitivities of tetherin isoforms to counteraction by primate lentiviruses.

Authors:  Julia Weinelt; Stuart J D Neil
Journal:  J Virol       Date:  2014-03-12       Impact factor: 5.103

9.  Vpu binds directly to tetherin and displaces it from nascent virions.

Authors:  Matthew W McNatt; Trinity Zang; Paul D Bieniasz
Journal:  PLoS Pathog       Date:  2013-04-25       Impact factor: 6.823

10.  Vpu downmodulates two distinct targets, tetherin and gibbon ape leukemia virus envelope, through shared features in the Vpu cytoplasmic tail.

Authors:  Tiffany M Lucas; Sanath K Janaka; Edward B Stephens; Marc C Johnson
Journal:  PLoS One       Date:  2012-12-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.